Clinical Trial Detail

NCT ID NCT03149159
Title Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Medical University of South Carolina
Indications

clear cell renal cell carcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.